 | Up a level |
Dziadziuszko, Rafal; Smit, Egbert F; Dafni, Urania; Wolf, Juergen; Wasąg, Bartosz; Biernat, Wojciech; Finn, Stephen P; Kammler, Roswitha; Tsourti, Zoi; Rabaglio, Manuela; Ruepp, Barbara; Roschitzki-Voser, Heidi; Stahel, Rolf A; Felip, Enriqueta; Peters, Solange (2019). Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Journal of thoracic oncology, 14(6), pp. 1086-1094. Elsevier 10.1016/j.jtho.2019.02.017
Loi, Sherene; Giobbie-Hurder, Anita; Gombos, Andrea; Bachelot, Thomas; Hui, Rina; Curigliano, Giuseppe; Campone, Mario; Biganzoli, Laura; Bonnefoi, Hervé; Jerusalem, Guy; Bartsch, Rupert; Rabaglio, Manuela-Poretti; Kammler, Roswitha; Maibach, Rudolf; Smyth, Mark J; Di Leo, Angelo; Colleoni, Marco; Viale, Giuseppe; Regan, Meredith M and André, Fabrice (2019). Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. The lancet oncology, 20(3), pp. 371-382. Elsevier 10.1016/S1470-2045(18)30812-X
Dellapasqua, Silvia; Gray, Kathryn P.; Munzone, Elisabetta; Rubino, Daniela; Gianni, Lorenzo; Johansson, Harriet; Viale, Giuseppe; Ribi, Karin; Bernhard, Jürg; Kammler, Roswitha; Maibach, Rudolf; Rabaglio, Manuela; Ruepp, Barbara; Di Leo, Angelo; Coates, Alan S.; Gelber, Richard D.; Regan, Meredith M.; Goldhirsch, Aron; Colleoni, Marco (2019). Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. Journal of clinical oncology, 37(5), pp. 386-395. American Society of Clinical Oncology 10.1200/JCO.18.00296
Johansson, Harriet; Gray, Kathryn P; Pagani, Olivia; Regan, Meredith M; Viale, Giuseppe; Aristarco, Valentina; Macis, Debora; Puccio, Antonella; Roux, Susanne; Maibach, Rudolf; Colleoni, Marco; Rabaglio, Manuela; Price, Karen N; Coates, Alan S; Gelber, Richard D; Goldhirsch, Aron; Kammler, Roswitha; Bonanni, Bernardo; Walley, Barbara A (2016). Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast cancer research, 18(1), p. 110. BioMed Central Ltd. 10.1186/s13058-016-0771-8
Regan, Meredith M.; Leyland-Jones, Brian; Bouzyk, Mark; Pagani, Olivia; Tang, Weining; Kammler, Roswitha; Dell’Orto, Patrizia; Biasi, Maria Olivia; Thürlimann, Beat; Lyng, Maria B.; Ditzel, Henrik J.; Neven, Patrick; Debled, Marc; Maibach, Rudolf; Price, Karen N.; Gelber, Richard D.; Coates, Alan S.; Goldhirsch, Aron; Rae, James M. and Viale, Giuseppe (2012). CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. Journal of the National Cancer Institute JNCI, 104(6), pp. 441-451. Oxford University Press 10.1093/jnci/djs125
